Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression (TRD) too high to offer value for money, says a US cost-effectiveness body. The Institute for Clinical ...
After the rejection of Lykos Therapeutics’ MDMA-based PTSD treatment tempered excitement for psychedelic therapeutics, a ...
Pharmaceutical Technology on MSN2d
Supernus’s stock sinks after depression drug fails trialThe company announced on 18 February that the trial did not meet its primary endpoint measured by a depression rating scale, ...
Months after Massachusetts voters rejected a ballot question that would permit adults to use and grow certain psychedelic ...
Spravato has been approved since 2019 for ... "This provides further evidence for the use of esketamine nasal spray in this difficult-to-treat population and offers hope for the millions of ...
The largest life sciences association in the state recognized those driving discovery during its 32nd annual dinner meeting ...
A Massachusetts man is the only one in the country who has tried a nasal spray treatment for Alzheimer's. He's going to help ...
Compared with placebo, zavegepant nasal spray yielded sustained relief of acute pain and function in migraine.
The neffyinSchools program from ARS Pharma will provide eligible public and private K-12 schools in the United States with ...
Almost 100,000 bottles of nasal spray were recalled for a "microbial failure" that led to multiple complaints from customers.
Medpage Today on MSN3d
Noted Neuroscientist Dies; Nasal Spray for Alzheimer's Disease; Benign MSA Massachusetts man became the first person to try intranasal foralumab under an expanded access program for people with ...
Johnson & Johnson is well-diversified across thriving healthcare segments, with promising FDA approvals. Read why I assign a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback